Funding for this research was provided by:
Associazione Italiana per la Ricerca sul Cancro (IG 18972)
Received: 6 March 2019
Accepted: 13 May 2019
First Online: 4 June 2019
Ethics approval and consent to participate
: The University of Campania “Luigi Vanvitelli” (Naples, Italy) and Candiolo Cancer Institute (Torino, Italy) approved this study.
: All authors agree on publication of the results of the present manuscript.
: TT: advisory board for Amgen, Bayer, Merck, Servier, Roche, Sanofi. EM: advisory board for Amgen, Bayer, Merck, Roche, Sanofi, Servier, Biocartis and expert opinion for ESMO (European Society of Medical Oncology).FM: advisory boards: MSD, Lilly; institutional research grants: AstraZeneca. FC: Advisory Boards, Bayer, Merck KgA, Roche, Servier, Amgen, Symphogen, Pfizer; Research funds, Roche, Bayer, Merck KgA, Ipsen, Amgen.LV: Symphogen, Merus, Pfizer, Servier, Eli Lilly, AstraZeneca, Merck. AB: Relay Therapeutics. VB, NM, SN, GM, FC, DC, VDF, EFG and UB declare no competing conflict of interest regarding the following manuscript.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.